Oftakviks 5 mg / ml 5 ml of eye drops
- $29.90
The instruction
for medical use
of OFTAKVIKS® medicine
the Trade name
of Oftakviks®
the International unlicensed
name Levofloxacin Dosage Form
of the Drop eye 5mg/ml
Structure
of 1 ml of solution contains
active agent: a levofloksatsina hemihydrate of 5.12 mg (it is equivalent to a levofloksatsin of 5.0 mg),
excipients: a benzalkoniya chloride, sodium chloride, Acidum hydrochloricum, sodium hydroxide, water for injections.
The description
Transparent solution from light yellow till light chartreuse color
Pharmacotherapeutic group
Drugs for treatment of diseases of eyes. Antimicrobial drugs.
Ftorkhinolona. Levofloxacin
ATX S01AE05 Code
the Pharmacological
Pharmacokinetics Later properties of instillation in an eye levofloxacin well remains in a plaintive film. Average concentration of a levofloksatsin in a plaintive film in 4 and 6 hours after topical administration makes 17.0 mkg/ml and 6.6 mkg/ml respectively.
Average concentration of a levofloksatsin of eye drops of Oftakviks® in watery moisture is approximately twice higher, than average concentration of an ofloksatsin (1139.9 ± 717.1 ng/ml and 621.7 ± 368.7 ng/ml respectively).
Average concentration of a levofloksatsin in blood plasma in 1 hour after use – from 0.86 ng/ml in the 1st day up to 2.05 ng/ml for 15 day. The maximum concentration of a levofloksatsin in plasma, equal 2.25 ng/ml, is revealed for the 4th day after two days of use of drug each 2 hours up to 8 times a day. The maximum concentration of a levofloksatsin increased from 0.94 ng/ml in the 1st day up to 2.15 ng/ml for the 15th day that is 1000 times lower, than its concentration after intake of standard doses of a levofloksatsin. Biot - absorption high - from 60 do100%.
The pharmacodynamics
of Oftakviks® whose active ingredient is levofloxacin is left-handed isomer of racemic substance of an ofloksatsin. The antibacterial activity of an ofloksatsin is mainly caused by left-handed isomer.
The action mechanism
As antibacterial drug of a class of ftorkhinolon, levofloxacin selectively inhibits bacterial II topoisomerase - DNK-girazu and topoisomerase IV. Preferable targets of a levofloksatsin in gram-negative bacteria is DNK-giraza, and in gram-positive topoisomerase IV. It is effective concerning the following microorganisms:
Category I: The most susceptible types
Aerobic Gram-positive: Staphylococcus aureus (MSSA) *, Staphylococcus pneumoniae, Staphylococcus pyogenes, Viridans group streptococci
Aerobic Gram-negative: Escherichia coli, Branhamella (Moraxella) catarrhalis, Haemophilus influenzae, Pseudomonas aeruginosa (local cultures)
Other microorganisms
of Chlamydia trachomatis (treatment of patients with chlamydial conjunctivitis demands the accompanying system antimicrobic therapy)
Category II: Types for which the acquired stability can be a problem
Aerobic Gram-positive microorganisms: Staphylococcus aureus (MRSA) **,
Staphylococcus epidermidis Aerobic Gram-negative micro-organisms Pseudomonas aeruginosa (hospital strains)
* MSSA = Methicillinum - sensitive strains of Staphylococcus aureus
** = Methicillinum - resistant strains of Staphylococcus aureus
Indications
- treatment of superficial bacterial infections of an eye at patients aged from 8 years is also more senior than MRSA
- prevention of complications after surgical and laser eye surgeries
the Route of administration and doses
Locally on 1-2 drop in one or both struck eyes each 2 hours up to 8 times a day within the first 2 days, then 4 times a day.
The usual duration of treatment is 5 days. Increase in a course of treatment up to 2 weeks is in certain cases possible.
At simultaneous use of other ophthalmologic means the interval between instillations has to be at least 15 minutes.
To avoid solution pollution, it is not necessary to touch with a tip of a dropper by centuries and fabrics around an eye.
Side effects
Side effects can arise approximately at 10% of patients. Side effects, as a rule, are shown in an easy or moderate form, have passing character and are usually limited to ophthalmologic symptoms. Drug as preservative contain a benzalkoniya chloride which, as well as active agent, can cause contact dermatitis, irritation of an eye or their combination.
The general (³1/100 & lt, 1/10)
- burning sensation in eyes
- decrease in visual acuity
- emergence of slime in a look tyazheyredky (³1/1.000 & lt, 1/100) - blepharitis, hemoz, conjunctival papillary reaction, swelled centuries, discomfort, an itching and eye pain, conjunctiva hyperaemia, conjunctiva follicles, xerophthalmus, an erythema a century, photophobia
- a headache
- rhinitis
Very rare (³1/10.000, & lt, 1/1.000)
- extraocular allergic reactions, including skin rash
Extremely rare (& lt, 1/10.000), (including separate messages)
- an anaphylaxis
-
the Contraindication laryngeal edema
- hypersensitivity to active agent — a levofloksatsin, other hinolona or any filler
- children's age up to 8 years
Medicinal interactions
are not revealed
Special instructions
Eye drops of Oftakviks®, 5 mg/ml cannot be entered subkonjyunktivalno. Eye drops should not be instillirovat directly in an anterior chamber of an eye.
Ftorkhinolona for system use can cause allergic reactions even after single use. At emergence of allergic reaction to levofloxacin it is necessary to stop use of eye drops.
As concerning all antimicrobic means, prolonged use of Oftakviksa® can lead to growth of resistant microorganisms, including fungi. If there is a deterioration in infectious manifestations or later a certain period of clinical improvement is not observed, it is necessary to stop use of drug and to appoint alternative therapy.
Eye drops of Oftaviks®, 5 mg/ml contain a benzalkoniya chloride as preservative and they should not be applied during carrying hydrophilic (soft) contact lenses as preservative can be absorbed and cause them irritation of an eye.
In the presence of symptoms of a superficial bacterial infection of eyes the patients should not use contact lenses.
Safety and efficiency of drug at treatment of a helcoma and gonococcal conjunctivitis of newborns are not studied.
Use for elderly: Change of a dosage is not required.
Pregnancy and the period of a lactation
pregnant women have no adequate data about uses of a levofloksatsin. The potential risk of drug for people is unknown. Levofloxacin comes to breast milk. However, when using Oftakviksa® in therapeutic doses, effects on the baby are not expected. Eye drops of Oftakviks®, 5 mg/ml it is possible to apply during pregnancy and feeding by a breast if the potential advantage for mother exceeds possible risk for the baby.
The feature of influence of medicine on ability to run the vehicle or potentially dangerous mechanisms
in case of any passing disorders of vision to the patient should recommend to be waited while the sight is not normalized, and only then to drive the car or to operate the mechanical equipment.
The overdose
the Total number of a levofloksatsin which is contained rolled into one eye drops is not enough to cause toxic reactions after accidental intake. After topical administration of an excess dose of eye drops of Oftakviks®, 5 mg/ml of eyes can be washed with clear (water) water of room temperature.
A form of release and packing
On 5 ml in a bottle polyethylene with a stopper dropper and the screw-on cap with a transparent film ring for control of the first opening.
1 bottle together with the instruction for medical use in the state and Russian languages is placed in a cardboard box.
To Store storage conditions at a temperature not above +25 °C.
To store out of children's reach!
A period of storage
3 years
After opening of a bottle – 1 month.
Not to use after the expiration date specified on packing.
Prescription status
According to the prescription
JSC Santen Producer, Finland, Tampere, 33720 Niittyhaankatu, 20
Name and the country of the owner of the registration certificate
of JSC Santen, Finland
the Address of the organization accepting in the territory of the Republic of Kazakhstan claims from consumers on quality of products (goods):
Representative office of JSC Canten in
Kazakhstan Panfilov St. 98, office 713, 05 0000 Almaty
the Phone number – 250-39-17
E-mail address: atlana.
To Develop khokina@santen.eu
for medical use
of OFTAKVIKS® medicine
the Trade name
of Oftakviks®
the International unlicensed
name Levofloxacin Dosage Form
of the Drop eye 5mg/ml
Structure
of 1 ml of solution contains
active agent: a levofloksatsina hemihydrate of 5.12 mg (it is equivalent to a levofloksatsin of 5.0 mg),
excipients: a benzalkoniya chloride, sodium chloride, Acidum hydrochloricum, sodium hydroxide, water for injections.
The description
Transparent solution from light yellow till light chartreuse color
Pharmacotherapeutic group
Drugs for treatment of diseases of eyes. Antimicrobial drugs.
Ftorkhinolona. Levofloxacin
ATX S01AE05 Code
the Pharmacological
Pharmacokinetics Later properties of instillation in an eye levofloxacin well remains in a plaintive film. Average concentration of a levofloksatsin in a plaintive film in 4 and 6 hours after topical administration makes 17.0 mkg/ml and 6.6 mkg/ml respectively.
Average concentration of a levofloksatsin of eye drops of Oftakviks® in watery moisture is approximately twice higher, than average concentration of an ofloksatsin (1139.9 ± 717.1 ng/ml and 621.7 ± 368.7 ng/ml respectively).
Average concentration of a levofloksatsin in blood plasma in 1 hour after use – from 0.86 ng/ml in the 1st day up to 2.05 ng/ml for 15 day. The maximum concentration of a levofloksatsin in plasma, equal 2.25 ng/ml, is revealed for the 4th day after two days of use of drug each 2 hours up to 8 times a day. The maximum concentration of a levofloksatsin increased from 0.94 ng/ml in the 1st day up to 2.15 ng/ml for the 15th day that is 1000 times lower, than its concentration after intake of standard doses of a levofloksatsin. Biot - absorption high - from 60 do100%.
The pharmacodynamics
of Oftakviks® whose active ingredient is levofloxacin is left-handed isomer of racemic substance of an ofloksatsin. The antibacterial activity of an ofloksatsin is mainly caused by left-handed isomer.
The action mechanism
As antibacterial drug of a class of ftorkhinolon, levofloxacin selectively inhibits bacterial II topoisomerase - DNK-girazu and topoisomerase IV. Preferable targets of a levofloksatsin in gram-negative bacteria is DNK-giraza, and in gram-positive topoisomerase IV. It is effective concerning the following microorganisms:
Category I: The most susceptible types
Aerobic Gram-positive: Staphylococcus aureus (MSSA) *, Staphylococcus pneumoniae, Staphylococcus pyogenes, Viridans group streptococci
Aerobic Gram-negative: Escherichia coli, Branhamella (Moraxella) catarrhalis, Haemophilus influenzae, Pseudomonas aeruginosa (local cultures)
Other microorganisms
of Chlamydia trachomatis (treatment of patients with chlamydial conjunctivitis demands the accompanying system antimicrobic therapy)
Category II: Types for which the acquired stability can be a problem
Aerobic Gram-positive microorganisms: Staphylococcus aureus (MRSA) **,
Staphylococcus epidermidis Aerobic Gram-negative micro-organisms Pseudomonas aeruginosa (hospital strains)
* MSSA = Methicillinum - sensitive strains of Staphylococcus aureus
** = Methicillinum - resistant strains of Staphylococcus aureus
Indications
- treatment of superficial bacterial infections of an eye at patients aged from 8 years is also more senior than MRSA
- prevention of complications after surgical and laser eye surgeries
the Route of administration and doses
Locally on 1-2 drop in one or both struck eyes each 2 hours up to 8 times a day within the first 2 days, then 4 times a day.
The usual duration of treatment is 5 days. Increase in a course of treatment up to 2 weeks is in certain cases possible.
At simultaneous use of other ophthalmologic means the interval between instillations has to be at least 15 minutes.
To avoid solution pollution, it is not necessary to touch with a tip of a dropper by centuries and fabrics around an eye.
Side effects
Side effects can arise approximately at 10% of patients. Side effects, as a rule, are shown in an easy or moderate form, have passing character and are usually limited to ophthalmologic symptoms. Drug as preservative contain a benzalkoniya chloride which, as well as active agent, can cause contact dermatitis, irritation of an eye or their combination.
The general (³1/100 & lt, 1/10)
- burning sensation in eyes
- decrease in visual acuity
- emergence of slime in a look tyazheyredky (³1/1.000 & lt, 1/100) - blepharitis, hemoz, conjunctival papillary reaction, swelled centuries, discomfort, an itching and eye pain, conjunctiva hyperaemia, conjunctiva follicles, xerophthalmus, an erythema a century, photophobia
- a headache
- rhinitis
Very rare (³1/10.000, & lt, 1/1.000)
- extraocular allergic reactions, including skin rash
Extremely rare (& lt, 1/10.000), (including separate messages)
- an anaphylaxis
-
the Contraindication laryngeal edema
- hypersensitivity to active agent — a levofloksatsin, other hinolona or any filler
- children's age up to 8 years
Medicinal interactions
are not revealed
Special instructions
Eye drops of Oftakviks®, 5 mg/ml cannot be entered subkonjyunktivalno. Eye drops should not be instillirovat directly in an anterior chamber of an eye.
Ftorkhinolona for system use can cause allergic reactions even after single use. At emergence of allergic reaction to levofloxacin it is necessary to stop use of eye drops.
As concerning all antimicrobic means, prolonged use of Oftakviksa® can lead to growth of resistant microorganisms, including fungi. If there is a deterioration in infectious manifestations or later a certain period of clinical improvement is not observed, it is necessary to stop use of drug and to appoint alternative therapy.
Eye drops of Oftaviks®, 5 mg/ml contain a benzalkoniya chloride as preservative and they should not be applied during carrying hydrophilic (soft) contact lenses as preservative can be absorbed and cause them irritation of an eye.
In the presence of symptoms of a superficial bacterial infection of eyes the patients should not use contact lenses.
Safety and efficiency of drug at treatment of a helcoma and gonococcal conjunctivitis of newborns are not studied.
Use for elderly: Change of a dosage is not required.
Pregnancy and the period of a lactation
pregnant women have no adequate data about uses of a levofloksatsin. The potential risk of drug for people is unknown. Levofloxacin comes to breast milk. However, when using Oftakviksa® in therapeutic doses, effects on the baby are not expected. Eye drops of Oftakviks®, 5 mg/ml it is possible to apply during pregnancy and feeding by a breast if the potential advantage for mother exceeds possible risk for the baby.
The feature of influence of medicine on ability to run the vehicle or potentially dangerous mechanisms
in case of any passing disorders of vision to the patient should recommend to be waited while the sight is not normalized, and only then to drive the car or to operate the mechanical equipment.
The overdose
the Total number of a levofloksatsin which is contained rolled into one eye drops is not enough to cause toxic reactions after accidental intake. After topical administration of an excess dose of eye drops of Oftakviks®, 5 mg/ml of eyes can be washed with clear (water) water of room temperature.
A form of release and packing
On 5 ml in a bottle polyethylene with a stopper dropper and the screw-on cap with a transparent film ring for control of the first opening.
1 bottle together with the instruction for medical use in the state and Russian languages is placed in a cardboard box.
To Store storage conditions at a temperature not above +25 °C.
To store out of children's reach!
A period of storage
3 years
After opening of a bottle – 1 month.
Not to use after the expiration date specified on packing.
Prescription status
According to the prescription
JSC Santen Producer, Finland, Tampere, 33720 Niittyhaankatu, 20
Name and the country of the owner of the registration certificate
of JSC Santen, Finland
the Address of the organization accepting in the territory of the Republic of Kazakhstan claims from consumers on quality of products (goods):
Representative office of JSC Canten in
Kazakhstan Panfilov St. 98, office 713, 05 0000 Almaty
the Phone number – 250-39-17
E-mail address: atlana.
To Develop khokina@santen.eu
Related Products
